HomeTrialNCT07177066
🔬NCT07177066Phase 1RECRUITING

A Study of EDG-15400 in Healthy Adults

Study Summary

The purposes of this Phase 1 study of EDG-15400 are to: 1. Learn about the safety of EDG-15400 after single and multiple doses in healthy adults 2. Learn about how EDG-15400 is tolerated after single and multiples doses in healthy adults 3. Evaluate the amount of EDG-15400 in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-15400 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-15400 in the blood is similar for the suspension and tablet forms of EDG-15400 in healthy adults Participants will receive a single or multiple doses of EDG-15400 or a placebo by mouth.

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment108 participants
Primary Completion
Lead SponsorEdgewise Therapeutics, Inc.
Data Retrieved2026-04-11 04:13:37.458688+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.